SensiVida Medical Technologies, Inc. Appoints Margaret Lydon as New COO and John P. Spoonhower as CTO and Showcases New Website

HENRIETTA, NY--(Marketwire - September 20, 2010) -

SensiVida Medical Technologies Inc. (PINKSHEETS: SVMT) is pleased to announce the appointment of Margaret Lydon, as the Company’s new Chief Operating Officer and John P. Spoonhower, as Chief Technology Officer.

A graduate of Saint John Fisher College, Ms. Lydon went on to receive her M.S. in Materials Science and Engineering from the Rochester Institute of Technology. She has over 20 years of experience in product development and general management in the medical device sector. Ms. Lydon has specialized expertise in the development and commercialization of polymer coated and drug-eluting medical devices. Ms. Lydon’s experience prior to SensiVida includes: working as a consultant for Isoflux Biomed; operating as General Manager at Angiotech BioCoatings Corporation; and holding the position of Vice President of Operations and Product Development for STS Biopolymers, Inc. In addition to her extensive experience managing daily operations, Ms. Lydon has directed a number of product development teams in the commercialization of novel medical devices. A video interview featuring Ms. Lydon can be viewed at: http://vimeo.com/12979119

Dr. John Spoonhower brings outstanding technical and scientific expertise to SensiVida. A graduate of the University of Notre Dame, Dr. Spoonhower received his B.S. in Physics and then went on to complete his M.S and Ph.D. in Applied and Engineering Physics from Cornell University. Prior to SensiVida, Dr. Spoonhower worked as Managing Director of the Innovation Interface at Cornell University and has also held several Cornell teaching positions. While working for the Eastman Kodak Company, he held a number of senior scientific and leadership positions, including Chief Technologist of a multi-national initiative responsible for incubating new businesses and products across Health, Commercial, and Government market segments. In addition, Dr. Spoonhower has co-authored 55 refereed publications and has been granted 56 patents, with five additional patents pending. He is a member of numerous Advisory Boards for NSF and New York State (NYSTAR) supported research centers. He is also a two-time CTO Patent Award winner from the Eastman Kodak Company. A video interview featuring Dr. Spoonhower can be viewed at: http://vimeo.com/11699335

More information about Margaret Lydon and John P. Spoonhower can be found at SensiVida’s new website, www.SensiVidamedical.com. On the Company’s renewed website, the visitor has the ability to watch personal interviews of those in management, including Ms. Lydon and Mr. Spoonhower. In addition, SensiVida’s new and improved website goes into greater detail regarding the Company’s products and technology, for both the general public and investors.

About SensiVida Medical Technologies, Inc.

SensiVida is a developer and provider of minimally invasive diagnostic devices with proprietary, microsystems-based technology that automates bio-sensing and data acquisition while minimizing patient discomfort. The Company’s optical-digital platform technology addresses a number of multi-billion dollar market opportunities: allergy testing, pain-free automated glucose monitors, blood coagulation testing, TB testing, cholesterol monitoring, and more.

SensiVida has an exclusive worldwide license to nine pending patents. In addition to the SensiVida allergy test, the product pipeline, based on the same microsystem and image processing technology, includes a portable glucose monitor. This device consists of a patch or chip having multiple, individually addressable sensors that are activated in accordance with the patient’s test schedule, automatically recording the patient’s glucose level without pain, bio-fouling or clogging. For more information about SensiVida, please visit www.sensividamedical.com

Forward Looking Statements:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company’s ability to implement its long range business plan for various applications of its technology; the company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company’s reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company’s financial position. See the Company’s most recent Quarterly Report on Form 10Q and related 8-K filings.